Evogene Ltd. (EVGN)
NASDAQ·Healthcare·Biotechnology
$0.78
+0.00%
Mkt Cap $6.67M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 5, 2026 | $275.00K | $314.00K | +14.18% | -$0.26 | -$0.61 | -134.62% | — | — |
| Q4 2025 Nov 20, 2025 | $275.00K | $312.00K | +13.45% | -$0.26 | -$0.31 | -19.23% | — | — |
| Q3 2025 Aug 28, 2025 | — | $884.00K | — | — | -$1.06 | — | — | — |
| Q3 2025 Aug 19, 2025 | $905.00K | $884.00K | -2.32% | -$0.63 | -$0.62 | +0.80% | — | — |
| Q2 2025 May 21, 2025 | $1.94M | $2.44M | +25.82% | -$0.63 | -$0.38 | +39.20% | — | — |
| Q1 2025 Mar 6, 2025 | $5.00M | $1.61M | -67.78% | -$0.72 | $0.06 | +108.33% | — | — |
| Q4 2024 Nov 21, 2024 | $3.63M | $1.74M | -52.00% | -$1.01 | -$1.31 | -29.70% | — | — |
| Q3 2024 Aug 22, 2024 | $800.00K | $605.00K | -24.38% | -$0.12 | -$1.06 | -783.33% | — | — |
| Q2 2024 May 23, 2024 | $3.50M | $4.19M | +19.71% | -$0.09 | -$0.80 | -788.89% | — | — |
| Q1 2024 Mar 7, 2024 | $3.50M | $578.00K | -83.49% | -$1.40 | -$1.30 | +7.14% | — | — |
| Q4 2023 Nov 15, 2023 | $910.00K | $3.77M | +313.96% | -$1.70 | -$0.80 | +52.94% | — | — |
| Q3 2023 Aug 17, 2023 | $1.04M | $654.00K | -37.12% | -$1.90 | -$1.70 | +10.53% | — | — |
| Q2 2023 May 18, 2023 | $880.00K | $641.00K | -27.16% | -$1.60 | -$1.50 | +6.25% | — | — |
| Q1 2023 Mar 9, 2023 | $630.00K | $660.00K | +4.76% | -$2.10 | -$0.70 | +66.67% | — | — |
| Q4 2022 Nov 17, 2022 | $234.67K | $466.00K | +98.58% | -$2.00 | -$1.60 | +20.00% | — | — |
| Q3 2022 Aug 31, 2022 | $230.67K | $312.00K | +35.26% | -$1.80 | -$2.10 | -16.67% | — | — |
| Q2 2022 May 26, 2022 | $309.00K | $237.00K | -23.30% | -$1.40 | -$2.00 | -42.86% | — | — |
| Q1 2022 Mar 10, 2022 | $184.33K | $311.00K | +68.72% | -$2.00 | -$1.80 | +10.00% | — | — |
| Q4 2021 Nov 17, 2021 | $270.00K | $151.00K | -44.07% | -$1.70 | -$1.90 | -11.76% | — | — |
| Q3 2021 Aug 11, 2021 | $300.00K | $135.00K | -55.00% | -$0.18 | -$1.50 | -733.33% | — | — |